THERAPY DOSSIER · th-5c8fe67635d0

Tartary buckwheat extract

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04403347 ↗NAcompleted

Effect of Tartary Buckwheat Diet Intervention on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration

Hypertension

Enrolment: 130 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32051738 ↗2020Reported benefit

Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway.

RatChemical/toxinMedium dose 16.70 mL/kg body weight

Model: Alcohol-induced acute and chronic liver injury in alcohol-exposed rats; alcohol-exposed primary cultured hepatocytes, HepG2 and Huh7 cells in vitro

Tartary buckwheat extract, similar to curcumin, reduced elevated serum aspartate aminotransferase and alanine aminotransferase, improved liver index, lowered hepatic malondialdehyde and restored hepatic glutathione in both acute and chronic alcohol-induced liver injury. A medium dose alleviated hep…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…